20 Years of hypertension research using genetically modified animals: No clinically promising approaches in sight

Altex

Volumn 26, Issue 1, 2009, Pages 41-51

  Stingl, Lavinia ^a   Völkel, Manfred ^b   Lindl, Toni ^a  

^a Institut für Angewandte Zellkultur   (Germany)

^b Tierversuchskommission Nordbayern   (Germany)

Author keywords

Diagnostic and therapeutic application; Genetically modified animals GMO; Primary hypertension; Target molecules

Indexed keywords

ANIMAL MODEL; BLOOD PRESSURE; DNA MODIFICATION; DRUG RESEARCH; GENETIC ANALYSIS; HYPERTENSION; MEDICAL RESEARCH; NONHUMAN; REVIEW; SPECIES DIFFERENTIATION; TRANSGENIC ANIMAL; ANIMAL; ANIMAL TESTING ALTERNATIVE; ARTICLE; HUMAN; MOUSE; PATHOPHYSIOLOGY; RAT; RESEARCH ETHICS;

ANTIHYPERTENSIVE AGENT;

ANIMAL TESTING ALTERNATIVES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIHYPERTENSIVE AGENTS; ETHICS, RESEARCH; HUMANS; HYPERTENSION; MICE; RATS;

EID: 66149108461     PISSN: 09467785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (173)

1. Aboul-Fadl, T. (2005). Antisense oligonucleotides: the state of the art. Curr. Med. Chem. 12, 2193-2214.
2. Abraham, N. G., Asija, A., Drummond, G., Peterson, S. (2007). Heme oxygenase-1 gene therapy: Recent advances and therapeutic applications. Curr. Gene Ther. 7, 89-108.
3. Agarwal, A. and Nick, H. S. (2000). Renal response to tissue injury: lessons from heme oxygenase-1 Gene ablation and expression. J. Am. Soc. Nephrol. 11, 965-973.
4. Agarwal, A., Williams, G. H. and Fisher, N. D. L. (2005). Genetics of human hypertension. Trends in Endocronolgy and Metabolism 16, 127-133.
5. Audoloy, L. P., Le, T. H. and Coffman, T. M. (2000). What can knockout mice contribute to an understanding of hypertension? Curr. Hypertens. Rep. 2, 192-197.
6. Bader, M., Bohnemeier, H., Zollmann, F. S. et al. (2000).Transgenic animals in cardiovascular disease research. Exp. Physiology 85, 713-731.
7. Banegas, I., Prieto, I., Vives, F. et al. (2006). Brain aminopeptidases and hypertension. J. Renin Angiotensin Aldosterone Syst. 7, 129-134.
8. Barbosa, M. E., Alenina, N. and Bader, M. (2005). Induction and analysis of cardiac hypertrophy in transgenic animal models. Methods Mol. Med. 112, 339-352.
9. Battistini, B., Berthiaume, N., Kelland, N. F. et al. (2006). Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp Biol. Med. 231, 653-695.
10. Beltowski, J., Jamroz, A. (2004). Adrenomedullin - what do we know 10 years since its discovery? Pol. J. Pharmacol. 56, 5-27. (Pubitemid 38515282)
11. Bernstein, K. E., Xiao, H. D., Adams, J. W. et al. (2005). Establishing the role of angiotensin-converting enzyme in renal function and blood pressure control through the analysis of genetically modified mice. J. Am. Soc. Nephrol. 16, 583-591.
12. Bernstein, K. E., Xiao, H. D., Frenzel, K. et al. (2005). Six truisms concerning ACE and the renin-angiotensin system edaced from the genetic analysis of mice. Circ Res. 96, 1135-1144.
13. Blank, R., Hobbs, F. D., Zamorano, J. and Girerd, X. (2007). A single-pill combination of amlodipine besylate and atorvastatin calcium (update). Drugs Today 43, 157-177. (Pubitemid 46661539)
14. Blaustein, M. P., Zhang, J., Chen, L. and Hamilton, B. P. (2006). How does salt retention raise blood pressure? Am. J. Physiol. Regul. Integr. Comp. Physiol. 290, R 514-523.
15. Bolli, M. H., Marfurt, J., Grisostomi, C. et al. (2004). Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists. J. Med. Chem. 47, 2776-2795.
16. Bray, M. S. and Boerwinkle, E. (2000). The role of beta(2)-adrenergic receptor variation in human hypertension. Curr. Hypertens. Rep. 2, 39-43.
17. Breyer, M. D. and Breyer, R. M. (2000). Prostaglandin E receptors and the kidney. Am. J. Physiol. Renal Physiol. 279, F12-23.
18. Breyer, M. D. and Breyer, R. M. (2000). Prostaglandin receptors: their role in regulating renal function. Curr. Opin. Nephrol. Hypertens. 9, 23-29.
19. Breyer, R. M., Kennedy, C. R., Zhang, Y. and Breyer, M. D. (2000). Structure-function analyses of eicosanoid receptors. Physiologic and therapeutic implications. Ann. N. Y. Acad. Sci. 905, 221-231.
20. Champy, M. F., Selloum, M., Piard, L. et al. (2004). Mouse functional genomics requires standardization of mouse handling and housing conditions. Mamm. Genome 15, 768-783. (Pubitemid 40012690)
21. Chao, J., Bledsoe, G., Yin, H. and Chao, L. (2006). The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. J. Biol. Chem. 387, 665-675.
22. Chao, J. and Chao, L. (2005). Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp. Physiol. 90, 291-298.
23. Chatziantoniou, C. and Dussaule, J. C. (2000). Endothelin and renal vascular fibrosis: of mice and men. Curr. Opin. Nephrol. Hypertens. 9, 31-36.
24. Chen, Y. H., Yet, S. F. and Perrella, M. A. (2003). Role of heme oxygenase-1 in the regulation of blood pressure and cardiac function. Exp. Biol. Med. 228, 447-453.
25. Cheng, M. F. and Fang, J. M. (2004). Liquid-phase combinatorial synthesis of 1,4-benzodiazepine-2,5-diones as the candidates of endothelin receptor antagonism. J. Comb. Chem. 6, 99-104.
26. Cogolludo, A., Perez-Vizcaino, F. and Tamargo, J. (2005). New insights in the pharmacological therapy of arterial hypertension. Curr. Opin. Nephrol. Hypertens. 14, 423-427.
27. Cooke, J. P. (2005). ADMA: its role in vascular disease. Vasc. Med. 10 (Suppl. 7), S11-17.
28. Crowley, S. D., Tharaux, P. L., Audoly, L. P. and Coffman, T. M. (2004). Exploring type I angiotensin (AT1) receptor functions through gene targeting. Acta Physio.l Scand. 181, 561-570.
29. Cogolludo, A., Perez-Vizcaino, F. and Tamargo, J. (2005). New insights in the pharmacological therapy of arterial hypertension. Curr. Opin. Nephrol. Hypertension 14, 423-427.
30. Cvetkovic, B. and Sigmund, C. D. (2000). Understanding hypertension through genetic manipulation in mice. Kidney Int. 57, 863-874.
31. Davenport, A. P. and Maguire, J. J. (2006). Endothelin. Handb. Exp. Pharmacol. 176, 295-329.
32. Davidson, M. J. and Koch, W. J. (2001). Genetic manipulation of beta-adrenergic signalling in heart failure. Acta Physiol. Scand. 173, 145-150.
33. Denton, K. M., Kett, M. M. and Dodic M. (2006). Programming hypertension - Animal models: causes and mechanisms. Adv. in Exp. Med. Biol. 573, 103-120.
34. Deng, P. Y. and Li, Y. J. (2005). Calcitonin gene-related peptide and hypertension. Peptides 26, 1676-1685.
35. Der Sarkissian, S., Huentelman, M. J., Stewart, J. et al. (2006). ACE2: A novel therapeutic target for cardiovascular diseases. Prog. Biophys. Mol. Biol. 91, 163-198.
36. Deshane, J., Wright, M. and Agarwal, A. (2005). Heme oxygenase-1 expression in disease states. Acta Biochim. Pol. 52, 273-284.
37. Doggrell, S. A. (2004). Is RGS-2 a new drug development target in cardiovascular disease? Expert Opin. Ther. Targets. 8, 355-358.
38. Dong, C. and Goldschmidt-Clermont, P. J. (2007). Endothelial progenitor cells: a promising therapeutic alternative for cardiovascular disease. J. Interv. Cardiol. 20, 93-99.
39. Escames, G., Khaldy, H., Leon, J. et al. (2004).Changes in iNOS activity, oxidative stress and melatonin levels in hypertensive patients treated with lacidipine. J. Hypertens. 22, 629-635. (Pubitemid 38368498)
40. Freedman, S. B. (2002). Clinical trials of gene therapy for atherosclerotic cardiovascular disease. Curr. Opin. Lipidol. 13, 653-661.
41. Fukamizu, A. (2000). Genomic expression systems on hierarchy and network leading to hypertension: long on history, short on facts. Hypertension Res. 23, 545-552.
42. Funakoshi, H., Chan, T. O., Good, J. C. et al. (2006). Regulated overexpression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and function. Circulation 114, 2240-2250. (Pubitemid 44789499)
43. Garcia, M. A., Martin-Santamaria, S., de Pascual-Teresa, B. et al. (2006). Adrenomedullin: a new and promising target for drug discovery. Expert Opin. Ther. Targets 10, 303-317.
44. Gelband, C. H., Katovich, M. J. and Raizada, M. K. (2000). Current perspectives on the use of gene therapy for hypertension. Circ. Res. 87, 1118-1122.
45. Guimaraes, S. and Moura, D. (2001). Vascular adrenoceptors: an update. Pharmacol. Rev. 53, 319-356.
46. Haefliger, J. A., Nicod, P. and Meda, P. (2004). Contribution of connexins to the function of the vascular wall. Cardiovasc. Res. 62, 345-56.
47. Halabi, C. M. and Sigmund, C. D. (2005). Peroxisome proliferator- activated receptor-gamma and its agonists in hypertension and atherosclerosis: mechanisms and clinical implications. Am. J. Cardiovasc. Drugs 5, 389-398.
48. Hansen, J. L., Theilade, J., Aplin, M. and Sheikh, S. P. (2006). Role of G-protein-coupled receptor kinase 2 in the heart. Do regulatory mechanisms open novel therapeutic perspectives? Trends Cardiovasc. Med. 16, 169-177.
49. Harris, R. C., Zhang, M. Z. and Cheng, H. F. (2004). Cyclooxygenase-2 and the renal renin-angiotensin system. Acta Physiol. Scand. 181, 543-547.
50. Hata, J. A., Williams, M. L. and Koch, W. J. (2004). Genetic manipulation of myocardial beta-adrenergic receptor activation and desensitization. J. Mol. Cell Cardiol. 37, 11-21.
51. Herrera, V. L. and Ruiz-Opazo, N. (2005). Genetic studies in rat models: insights into cardiovascular disease. Curr. Opin. Lipidol. 16, 119-191.
52. Heistad, D. D. (2006). Gene therapy for vascular disease. Vascal. Pharmacol. 45, 331-333.
53. Hill-Kapturczak, N., Chang, S. H. and Agarwal, A. (2002). Heme oxygenase and the kidney. DNA Cell Biol. 21, 307-321.
54. Hirooka, Y., Kishi, T., Sakai, K. et al. (2003). Effect of overproduction of nitric oxide in the brain stem on the cardiovascular response in conscious rats. J. Cardiovasc. Pharmacol. 41, S119-126.
55. Hirsch, E., Lembo, G., Montrucchio, G. et al. (2006). Signaling through PI3Kgamma: a common platform for leukocyte, platelet and cardiovascular stress sensing. Thromb. Haemost. 95, 29-35.
56. Imig, J. D. (2006). Eicosanoids and renal vascular function in diseases. Clin. Sci. (Lond) 111, 21-34.
57. Imming, P., Sinning, C. and Meyer, A. (2007). Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov. 5, 821-34.
58. Israili, Z. H., Hernandez-Hernandez, R. and Valasco, M. (2007). The future of antihypertensive treatment. Am. J. Ther. 14, 121-134.
59. 2+ exchanger: implications for the pathogenesis and therapy of salt-dependent hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290, R 536-545.
60. Kable, J. W., Murrin, L. C. and Bylund, D. B. (2000). In vivo gene modification elucidates subtype-specific functions of alpha(2)-adrenergic receptors. J. Pharmacol. Exp. Ther. 293, 1-7.
61. Kamanaka, Y., Kawabata, A., Matsuya, H. et al. (2003). Effect of a potent iNOS inhibitor (ONO-1714) on acetaminophen-induced hepatotoxicity in the rat. Life Sci. 74, 793-802. (Pubitemid 37494905)
62. Kanagy, N. L. (2005). Alpha(2)-adrenergic receptor signalling in hypertension. Clin. Sci. (Lond) 109, 431-437.
63. Kapoor, K. and Dikshit, M. (2005). Transgenic and gene-knockout rodents as research tools for cardiovascular disordersScand. J. Lab. Animal Sc. 32, 49-67.
64. Katori, M. and Majima, M. (2003). The renal kallikrein-kinin system: its role as a safety valve for excess sodium intake, and its attenuation as a possible etiologic factor in salt-sensitive hypertension. Crit. Rev. Clin. Lab. Sci. 40, 43-115.
65. Keys, J. R. and Koc,h W. J. (2004). The adrenergic pathway and heart failure. Recent Prog. Horm. Res. 59, 13-30.
66. Khurana, R., Martin, J. F., Zachary, I. (2001). Gene therapy for cardiovascular disease: a case for cautious optimism. Hypertension 38, 1210-1216. (Pubitemid 34252833)
67. Khurana, R., Simons, M., Martin, J. F. and Zachary, I. C. (2005). Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 112, 1813-1824.
68. Kim, D.D., Pica, A.M., Duran, R. G. and Duran, W. N. (2006). Acupuncture reduces experimental renovascular hypertension through mechanisms involving nitric oxide synthases. Microcirculation.13, 577-585.
69. Kim, T., Loh, Y. P. (2005). Chromogranin A: a surprising link between granule biogenesis and hypertension. J. Clin. Invest. 115, 1711-1713.
70. Kirkby, K. A. and Adin, C. A. (2006). Products of heme oxygenase and their potential therapeutic applications. Am. J. Physiol. Renal. Physiol. 290, F 563-571.
71. Koch, W. J. (2002). Gene transfer of beta-adrenergic signaling components for heart failure. J. Card. Fail. 8, S 526-531.
72. Kohan, D. E. (2006). The renal medullary endothelin system in control of sodium and water excretion and systemic blood pressure. Curr. Opin. Nephrol. Hypertens. 15, 34-40.
73. Kurihara, H. (2001). Symposium on the etiology of hypertension - summarizing studies in 20th century. 2. Genetic engineering in hypertension research. Intern. Med. 40, 147-151.
74. Landmesser, U., Cai, H., Dikalov, S. et al. (2002). Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 40, 511-515.
75. Lake-Bruse, K. D. and Sigmund, C. D. (2000). Transgenic and knockout mice to study the renin-angiotensin system and other interacting vasoactive pathways. Curr. Hypertens. Rep. 2, 211-216.
76. Lavoie, J. L., Bianco, R. A., Sakai, K. et al. (2004). Transgenic mice for studies of the renin-angiotensin system in hypertension. Acta Physiol. Scand. 181, 511-511.
77. Le, T. H. and Coffman, T. M. (2003). RGS2: a "turn-off" in hypertension. J. Clin. Invest. 111, 441-443.
78. Leighton, F., Miranda-Rottmann, S. and Urquiaga, I. (2006). A central role of eNOS in the protective effect of wine against metabolic syndrome. Cell. Biochem. Funct. 24, 291-298.
79. Lerman, L. O., Chade, A. R., Sica, V. and Napoli, C. (2005). Animal models of hypertension: an overview. J. Lab. Clin. Med. 146, 160-173.
80. Li, H., Gao, Y., Grobe, J. L. et al. (2007). Potentiation of the antihypertensive action of losartan by peripheral overexpression of the ANG II type 2 receptor. Am. J. Physiol. Heart Circ. Physiol. 292, H727-735.
81. Lindl, T., Völkel, M. and Kolar, R. (2005). Tierversuche in der biomedizinischen Forschung. ALTEX 22, 143-151.
82. Lindsay, M. A. (2005). Finding new drug targets in the 21st century. Drug Discovery Today 10, 1683-1687.
83. Liu, K. L., Chen, H. W., Wang, R. Y. et al. (2006). DATS reduces LPS-induced iNOS expression, NO production, oxidative stress, and NF-kappaB activation in RAW 264.7 macrophages. J. Agric. Food Client. 54, 3472-3478.
84. Liu, J. C., Chen, J. J., Chan, P. et al. (2003). Inhibition of cyclic strain-induced endothelin-1 gene expression by resveratrol. Hypertension 42, 1198-1205. (Pubitemid 37549077)
85. Malecki, M., Kolsut, P. and Proczka, R. (2005). Angiogenic and antiangiogenic gene therapy. Gene Titer. 12, S159-169.
86. Marcondes, S. and Antunes, E. (2005). The plasma and tissue kininogen-kallikrein-kinin system: role in the cardiovascular system. Curr. Med. Chem. Cardiovasc. Hematol. Agents. 3, 33-44.
87. Marquez-Rodas, I., Longo, F., Rothlin, R. P. and Balfagon, G. (2006). Pathophysiology and therapeutic possibilities of calcitonin gene-related peptide in hypertension. J. Physiol. Biochem. 62, 45-56.
88. Marteau, J. B., Zaiou, M., Siest, G. and Visvikis-Siest, S. (2005). Genetic determinants of blood pressure regulation. J. Hypertens. 23, 2127-43. (Pubitemid 41666740)
89. Martin-Ventura, J. L., Tunon, J., Duran, M. C. et al. (2006). Vascular protection of dual therapy (atorvastatin-amlodipine) in hypertensive patients. J. Am. Soc. Nephrol. 17, S189-193.
90. McBride, M. W., Graham, D., Delles, C. and Dominiczak, A. F. (2006). Functional genomics in hypertension. Curr. Opin. Nephrol. Hypertens. 15, 145-151.
91. Melo, L. G., Gnecchi, M., Pachori, A. S. et al. (2004). Endothelium-targeted gene and cell-based therapies for cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 24, 1761-1774.
92. Melo, L. G., Pachori, A. S., Gnecchi, M. and Dzau, V. J. (2005). Genetic therapies for cardiovascular diseases. Trends Mol. Med. 11, 240-250.
93. Melo, L. G., Steinhelper, M. E., Pang, S. C. et al. (2000). ANP in regulation of arterial pressure and fluid-electrolyte balance: lessons from genetic mouse models. Physiol. Genomics 29, 45-58.
94. Metaye, T., Gibelin, H., Perdrisot, R. and Kraimps, J. L. (2005). Pathophysiological roles of G-protein-coupled receptor kinases. Cell Signal. 17, 917-28.
95. Metaye, T., Perdrisot, R., Kraimps, J. L. (2006). GRKs and arrestins: the therapeutic pathway? Med. Sci. (Paris) 22, 537-43.
96. Miriyala, S., Gongora Nieto, M. C., Mingone, C. et al. (2006). Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation. Circulation. 113, 2818-25. (Pubitemid 44305294)
97. Moens, A. L. and Kass, D. A. (2006). Tetrahydrobiopterin and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 26, 2439-2444.
98. Moore, J. H., Gilbert, J. C., Tsai, C. T. et al. (2006). A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. J. Theor. Biol. 241, 252-261.
99. Moro, C. and Berlan, M.(2006). Cardiovascular and metabolic effects of natriuretic peptides. Fundam. Clin. Pharmacol. 1, 41-49.
100. Muller, D. N., Fiebeler, A., Park, J. K. et al. (2003). Angiotensin II and endothelin induce inflammation and thereby promote hypertension-induced end-organ damage. Clin. Nephrol. 60, S 2-12.
101. Muller, D. N. and Luft, F. C. (2006). Direct renin inhibition with aliskiren in hypertension and target organ damage. Clinical Journal of the American Society of Nephrology 1, 221-228
102. Muller, D. N., Theuer, J., Shagdarsuren, E. et al. (2004). A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin H-induced renal injury. Am. J. Pathol. 164, 521-532.
103. Mullins, L. J., Bailey, M. A. and Mullins, J. J. (2006). Hypertension, kidney, and transgenics: a fresh perspective. Physiol. Rev. 86, 709-746.
104. Mullins, L. J., Bailey, M. A. and Mullins, J. J. (2006). Hypertension, kidney, and transgenics: a fresh perspective. Physiol. Rev. 86, 709-746.
105. Mukaddam-Daher, S. (2006). Natriuretic peptides as therapeutic targets. Expert Opin. Titer. Targets. 10, 239-252.
106. Mullins, L. J. and Mullins, J. (2003). Current successes and limitations of using genetic modification for blood pressure research. Pflugers Arch. 445, 491-494. (Pubitemid 36222997)
107. Nakamura, Y., Kogure, K., Yamada, Y. et al. (2006). Significant and prolonged antisense effect of a multifunctional envelopetype nano device encapsulating antisense oligodeoxynucleotide. J. Pharm. Pharmacol. 58, 431-437.
108. Nascimento-Silva, V., Arruda, M. A., Barja-Fidalgo, C. et al. (2005). Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. Am. J. Physiol. Cell Physiol. 289, C 557-563.
109. Nickenig, G., Ostergren, J. and Struijker-Boudier, H. (2006). Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers. J. Renin Angiotensin Aldosterone Syst. 7, S1-7.
110. Niu, T., Chen X. and Xu X. (2002). Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications. Drugs 62, 977-993. (Pubitemid 34533759)
111. Nordlie, M. A., Wold, L. E., Simkhovich, B. Z. et al. (2006). Molecular aspects of ischemic heart disease: ischemia/reperfusion-induced genetic changes and potential applications of gene and RNA interference therapy. J. Cardiovasc. Pharmacol. Ther. 11, 17-30.
112. O'Connell, D. P. and Aherne, A. M. (2000). Renal dopaminergic mechanisms and hypertension: a chronology of advances. Clin. Exp. Hypertens. 22, 217-249.
113. O'Connell, T. D., Swigart, P. M., Rodrigo, M. C. et al. (2006). Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload. J. Clin. Invest. 116, 1005-1015.
114. Omoni, A. O. and Aluko, R. E. (2006). Effect of cationic flaxseed protein hydrolysate fractions on the in vitro structure and activity of calmodulin-dependent endothelial nitric oxide synthase. Mol. Nutr. Food Res. 50, 958-966.
115. Opay, A. L., Mouton, C. R., Mullins, J. J. and Mitchell, K. D. (2006). Cyclooxygenase-2 inhibition normalizes arterial blood pressure in CYP1A1-REN2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am. J. Physiol. Renal Physiol. 291, F 612-618.
116. Oudit, G. Y., Sun, H., Kerfant, B. G. et al. (2004). The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J. Mol. Cell Cardiol. 37, 449-471.
117. Ozono, R. (2004). New biotechnological methods to reduce oxidative stress in the cardiovascular system: focusing on the Bach1/heme oxygenase-1 pathway. Curr. Pharm. Biotechnol. 7, 87-93.
118. Pedrazzini, T. (2004). Importance of NPY Y1 receptor-mediated pathways: assessment using NPY Y1 receptor knockouts. Neuropeptides 38, 267-275.
119. Perdicakis, B., Montgomery, H. J., Abbott, G. L. et al. (2005). Photocontrol of nitric oxide production in cell culture using a caged isoform selective inhibitor. Bioorg. Med. Client. 13, 47-57.
120. Perrella, M. A. and Yet, S. F. (2003). Role of heme oxygenase-1 in cardiovascular function. Curr. Pharm. Des. 9, 2479-2487.
121. Petrofski, J. A. and Koch, W. J. (2003). The beta-adrenergic receptor kinase in heart failure. J. Mol. Cell. Cardiol. 35, 1167-1174.
122. Phillips, M. I., Galli, S. M. and Mehta, J. L. (2000). The potential role of antisense oligodeoxynucleotide therapy for cardiovascular disease. Drugs 60, 239-248.
123. Phillips, M. I. (2000). Somatic gene therapy for hypertension. Braz. J. Med. Biol. Res. 33, 715-721.
124. Phillips, M. I. (2001). Gene therapy for hypertension: the preclinical data. Hypertension 38, 543-548.
125. Pilz, B., Shagdarsuren, E., Wellner, M. et al. (2005). Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46, 569-576. (Pubitemid 41376839)
126. Pleger, S. T., Remppis, A., Heidt, B. et al. (2005). S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. Mol. Ther. 12, 1120-1129.
127. Puddu, G. M. (2006). Gene-based therapy for hypertension: do preclinical data suggest a promising future? Cardiology 108, 40-47.
128. Quarck, R. and Holvoet, P. (2004). Gene therapy approaches for cardiovascular diseases. Curr. Gene Ther. 4, 207-223.
129. Queen, L. R. and Ferro, A. (2006). Beta-adrenergic receptors and nitric oxide generation in the cardiovascular system. Cell Mol. Life Sci. 63, 1070-1083.
130. Raizada, M. K. and Der Sarkissian, S. (2006). Potential of gene therapy strategy for the treatment of hypertension. Hypertension 47, 6-9. (Pubitemid 43177805)
131. Rao, F., Wen, G., Gayen, J. R. et al. (2007). Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 115, 2271-2281. (Pubitemid 46685895)
132. Rang, H. P., Dale, M. M., Ritter, J. M. and Moore, P. K. (2003). Pharmacology, 5th Edition, Edinbourgh, London: Churchill Livingstone.
133. Rosskopf, D., Schurks, M., Rimmbach, C. and Schafers, R. (2007). Genetics of arterial hypertension and hypotension. Naunyn Schmiedebergs Arch. Pharmacol. 374, 429-469.
134. Schellings, M. W., Baumann, M., van Leeuwen, R. E. et al. (2006). Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension 47, 467-474. (Pubitemid 43740292)
135. Schillinger, K. J., Tsai, S. Y., Taffet, G. E. et al. (2006). Regulable atrial natriuretic peptide gene therapy for hypertension. Proc. Natl. Acad. Sci. USA. 102, 13789-13794.
136. Scott, B. B., McGeehan, G. M. and Harrison, R. K. (2006). Development of inhibitors of the aspartyl protease renin for the treatment of hypertension. Curr. Protein Pept. Sci. 7, 241-254.
137. Semplicini, A., Lenzini, L., Sartori, M. et al. (2006). Reduced expression of regulator of G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. J. Hypertens. 24, 1115-1124. (Pubitemid 43772320)
138. Serrano, A. L. and Andres, V. (2004). Telomeres and cardiovascular disease: does size matter? Circ. Res. 94, 575-84.
139. Sever, P. S., Poulter, N. R., Elliott, W. J. et al. (2006). Blood pressure reduction is not the only determinant of outcome. Circulation 113, 2754-2774.
140. Shen, L. J., Lin, W. C., Beloussow, K. et al. (2003). Recombinant arginine deiminase as a differential modulator of inducible (iNOS) and endothelial (eNOS) nitric oxide synthetase activity in cultured endothelial cells. Biochem. Pharmacol. 66, 1945-1952.
141. Shimosawa, T. and Fujita, T. (2005). Adrenomedullin as a potent antioxidative and antiatherosclerotic substance. Drug News Perspect. 18, 185-189. (Pubitemid 40704840)
142. Shimosawa, T., Matsui, H., Xing, G. et al. (2003). Organ-protective effects of adrenomedullin. Hypertens. Res. 26, S109-112.
143. Sierra, C. and Ruilope, L. M. (2004). Role of the selective aldosterone receptor blockers in arterial hypertension. J. Renin Angiotensin Aldosterone Syst. 5, 23-25.
144. Siest, G., Jeannesson, E., Berrahmoune, H. et al. (2004) Pharmacogenomics and drug response in cardiovascular disorders. Pharmacogenomics 5, 779-802. (Pubitemid 39386749)
145. Simonson, O. E., Svahn, M. G., Tornquist, E. et al. (2005). Bioplex technology: novel synthetic gene delivery pharmaceutical based on peptides anchored to nucleic acids. Curr. Pharm. Des. 11, 3671-3680.
146. Smithies, O. (2005). Many little things: one geneticist's view of complex diseases. Nat. Rev. Genet. 6, 419-425.
147. Sturtevant, F. M. (1958). Antihypertensive effects of an aldosterone antagonist. Science 127, 1393-1394.
148. Sugiyama, F., Yagami, K. and Paigen, B. (2001). Mouse models of blood pressure regulation and hypertension. Curr. Hypertens. Rep. 3, 41-48.
149. Suzuki, H., Frank, G. D., Utsunomiya, H. et al. (2006). Current understanding of the mechanism and role of ROS in angiotensin II signal transduction. Curr. Pharm. Biotechnol. 2, 81-86.
150. Takahashi, N. and Smithies, O. (2004). Human genetics, animal models and computer simulations for studying hypertension. Trends Genet. 20, 136-145. (Pubitemid 38230028)
151. Takimoto, E., Champion, H. C., Li, M. et al. (2005). Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J. Clin. Invest. 115, 1221-1231.
152. Tang, K. M., Wang, G. R., Lu, P. et al. (2003). Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nature Med. 12, 1506-1512. (Pubitemid 38004778)
153. Tesson, L., Cozzi, J., Menoret, S. et al. (2005). Transgenic modifications of the rat genome. Transgenic Res. 14, 531-546. (Pubitemid 41509177)
154. Touyz, R. M. and Schiffrin, E. L. (2006). Peroxisome proliferator- activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul. Pharmacol. 45, 19-28.
155. Touyz, R. M. (2004). Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 44, 248-252.
156. Ushikubi, F., Sugimoto, Y., Ichikawa, A. and Narumiya, S. (2000). Roles of prostanoids revealed from studies using mice lacking specific prostanoid receptors. Jpn. J. Pharmacol. 83, 279-285.
157. Veerasingham, S. J., Sellers, K. W. and Raizada, M. K. (2004). Functional genomics as an emerging strategy for the investigation of central mechanisms in experimental hypertension. Prog. Biophys. Mol. Biol. 84, 107-123.
158. Walsh, D. A. and McWilliams, D. F. (2006). Tachykinins and the cardiovascular system. Curr. Drug Targets. 7, 1031-1042.
159. Wang, L., Menendez, P., Cerdan, C. and Bhatia, M. (2005). Hematopoietic development from human embryonic stem cell lines. Exp. Hematol. 33, 987-996.
160. Watson, R. E., Supowit, S. C., Zhao, H. et al. (2002). Role of sensory nervous system vasoactive peptides in hypertension. Braz. J. Med, Biol. Res. 35, 1033-1045.
161. Wilcox, C. S. (2005). Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am. J. Physiol. Regul. Integr. Comp. Physiol. 289, R913-935.
162. Wilcox, C. S. (2006). Special feature: Cardiovascular-kidney interactions in health and disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290, R34-R36.
163. Williams, M. (2003). Target validation. Curr. Opin. Pharmacol. 3, 571-577.
164. Wu, L. and Wang, R. (2005). Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol. Rev. 57, 585-630.
165. Yagil, Y. and Yagil, C. (2001). Genetic models of hypertension in experimental animals. Exp. Nephrol. 9, 1-9.
166. Yang, Z., Sibley, D. R. and Jose, P. A. (2004). D5 dopamine receptor knockout mice and hypertension. J. Recept. Signal Transduct. Res. 24, 149-164.
167. Yasunari, K., Maeda, K., Nakamura, M. et al. (2005). Left ventricular hypertrophy and angiotensin II receptor blocking agents. Curr. Med. Client. Cardiovasc. Hematol. Agents 3, 61-67.
168. Vauquelin, G., Michotte, Y., Smolders, I. et al. (2002). Cellular targets for angiotensin II fragments: pharmacological and molecular evidence. J. Renin Angiotensin Aldosterone Syst. 3, 195-204. (Pubitemid 36187374)
169. Zambrowicz, B. P. and Sands, A. T. (2003). Knockouts model the 100 best-selling drugs - will they model the next 100? Nat. Rev. Drug. Discov. 2, 38-51.
170. Zeng, C., Felder, R. A., Jose, P. A. (2006). A new approach for treatment of hypertension: modifying D1 dopamine receptor function. Cardiovasc. Hematol. Agents Med. Client. 4, 369-377.
171. Zeng, C., Sanada, H., Watanabe, H. et al. (2004). Functional genomics of the dopaminergic system in hypertension. Physiol. Genomics 19, 233-246.
172. Zhang, P., Xu, X., Hu, X. et al. (2007). Inducible nitric oxide synthase deficiency protects the heart from systolic overloadinduced ventricular hypertrophy and congestive heart failure. Circ.Res. 100, 1089-1098. (Pubitemid 46598934)
173. Zhu, Y. C., Zhu, Y. Z. and Moore, P. K. (2006). The role of urotensin II in cardiovascular and renal physiology and diseases. Br. J. Pharmacol. 148, 884-901.